Gavreto：基石藥業宣佈GAVRETO(R) (pralsetinib) 在中國香港獲批用 ...
基石藥業宣佈GAVRETO(R) (pralsetinib) 在中國香港獲批用 ...
Gavreto
https://www.ema.europa.eu
Gavreto is a cancer medicine for treating adults with advanced non-small cell lung cancer caused by changes in a gene called RET (known as RET ...
Gavreto® (pralsetinib)
https://www.gene.com
Get answers to your questions about your Gavreto prescription. SUPPORT. Medicine Information Support Ask about possible side effects and any other medical ...
GAVRETO® (pralsetinib)
https://www.gavreto-hcp.com
GAVRETO® (pralsetinib) is indicated for the treatment of: Adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell ...
Gavreto® (pralsetinib)藥品安全資訊風險溝通表
https://www.tdrf.org.tw
適用於治療局部晚期或轉移的RET融合陽性非小細胞肺癌(non-small cell lung cancer, NSCLC)成人病人；; 適用於需接受全身性治療的晚期或轉移的RET突變 ...
Home
https://www.gavreto.com
GAVRETO, also known as pralsetinib, is a targeted therapy that is taken by mouth once daily. It is used to treat certain cancers caused by abnormal RET genes.
【轉知】衛生福利部食品藥物管理署函文周知「Gavreto ...
https://www.patientsafety.mohw
歐洲藥品管理局(EMA) 提醒Gavreto® (pralsetinib)具有增加結核病的風險。在病人開始Gavreto® (pralsetinib)治療前，建議進行活動性和潛伏性結核病的評估。